Boston Scientific appoints new lead independent director and updates executive compensation plans
At a glance
- $BSX today−1.51%last $43.03
- Vs industry peers−2.00 pts6-peer median +0.49% · behind
- Since it broke0.00%from the first trade after the story
- 52-week range8.7% above low$39.57 – $101.91
- Last reported profit$580.0Mquarter to Sep 30, 2026 · 10-Q
- Coverage1 this week4 in 30 days · too few stories to call a pace
- Key person: Filed with SEC
- Clear: legal, regulatory, security, operational, financial integrity
Options price an average move of ±9.0% by Dec 18 — the at-the-money straddle, the typical size of the move; the bands are one standard deviation.
Early signals (1) — filed with the SEC or first reported, not yet widely covered
- Key person · SEC 8-K, Item 5.02, Nov 17: Filed: a director or officer departed, was appointed, or had their pay changed. View filing →
Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.
What it means
- What to watch: Drugmakers live and die by pipelines — what is in late-stage trials matters more than this quarter's sales.
- How the stock is trading: $BSX -1.51% in the latest session.
- Timing: It was published after the close, so the day's move was settled before the story existed. The next session is the first that could react.
Where the stock stands
Boston Scientific ($BSX) fell 1.51% to $43.03 in the latest session. Over the past month it is down 4.5%. It now sits 58% under the 52-week high of $101.91 and 8.7% above the year's low of $39.57, close to the bottom of its range. The year's high was 2.6 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 2, 2026), $BSX earned $580.0M over the quarter to Sep 30, 2026 on revenue of $5.14B (-5.6% QoQ). Operations brought in $2.87B of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $2.32B. The company filed an 8-K — the form for material events — on Nov 17, the same day as this story; it is $BSX's own account and the first thing to read. Figures are as filed with the SEC; the $BSX page has the full statements.
How much coverage it is getting
Wook has filed 4 stories on Boston Scientific in the last 30 days, 1 of them this week. That is about its usual pace: over the month it has averaged about 1 a week. Going by their wording, 0 read bullish, 3 neutral and 1 bearish. This one reads neutral too, in line with most of them. Investing.com wrote 4 of the 4 (100%), so the count reflects one outlet's output more than broad attention.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $BSX page, and they say what management has disclosed without a reporter in between. Most of the recent coverage comes from one outlet, so check whether another newsroom has confirmed the story or is only repeating it. Wook AI, at the top of the page, can work out how far $BSX is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 17, 2026. $BSX has moved +0.00% ($43.03 to $43.03). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
